| Pack Size/Qty | Price | Unit Price | |
| 240 Tablet/s | $360.00 | $1.50 | |
| 120 Tablet/s | $182.00 | $1.52 |
Generic Name : Nexavar
Brand Name : Sorafenib
Manufacturer Name : Cipla Ltd - Pharmaceutical Company
Product Code : CRX 72
Delivery Days : 10 to 15 working days
Strength : 200 mg
Packaging : Tablet/s (Blister Packing)
Soranib 200 mg is a potent pharmaceutical product that belongs to a class of medications known as tyrosine kinase inhibitors (TKIs). It is primarily used in the treatment of certain types of cancer, most notably renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and thyroid carcinoma. The active ingredient in Soranib is sorafenib, which exerts its therapeutic effects by targeting specific molecular pathways involved in tumor growth and progression.
Soranib 200 mg is manufactured by a reputable pharmaceutical company and is available in the form of oral tablets. Each tablet contains 200 mg of sorafenib, and it is typically prescribed by healthcare professionals who specialize in the treatment of cancer. The drug is an essential component of targeted therapy, which has revolutionized the field of oncology by focusing on specific molecules and processes responsible for the development and spread of cancer.
To understand the significance of Soranib 200 mg, let's delve into the science behind it and the conditions it is designed to treat:
Soranib 200 mg primarily works by inhibiting multiple protein kinases that play a crucial role in cancer cell growth and angiogenesis, the process of forming new blood vessels to supply tumors with nutrients. One of the primary molecular targets of sorafenib is the vascular endothelial growth factor receptor (VEGFR), which is essential for the formation of blood vessels that nourish the tumor. By inhibiting VEGFR, Soranib interferes with the tumor's blood supply, starving it of essential nutrients, and thereby slowing its growth.
Another key target of sorafenib is the receptor for platelet-derived growth factor (PDGFR), which is involved in cell proliferation. By blocking this receptor, Soranib 200 mg helps control the uncontrolled cell division that characterizes many cancers. Additionally, sorafenib inhibits the RAF/MEK/ERK signaling pathway, which is frequently overactive in cancer cells. This further contributes to the drug's ability to slow down the growth and division of cancer cells.
Renal Cell Carcinoma (RCC): Soranib 200 mg is approved for the treatment of advanced renal cell carcinoma, the most common type of kidney cancer in adults. It is typically prescribed when RCC is in its advanced stages or has spread to other parts of the body. The drug has been shown to increase the overall survival and progression-free survival of patients with RCC.
Hepatocellular Carcinoma (HCC): Soranib is also used for the treatment of hepatocellular carcinoma, which is the most common type of liver cancer. HCC often presents with limited treatment options, and Soranib 200 mg provides a valuable option in managing this aggressive cancer.
Thyroid Carcinoma: In certain cases, Soranib may be used to treat thyroid carcinoma, specifically differentiated thyroid carcinoma that is refractory to radioactive iodine therapy or not amenable to surgical resection.
Soranib 200 mg is administered orally in the form of tablets. It is usually taken once or twice daily, as directed by a healthcare professional. The exact dosage and duration of treatment will depend on the patient's specific condition and medical history. It is important to follow the prescribing doctor's instructions and to take the medication consistently for the best treatment outcomes.
Like many medications, Soranib 200 mg can cause side effects. Common side effects may include diarrhea, hand-foot skin reaction (a skin condition characterized by redness, swelling, and pain on the palms of the hands and soles of the feet), rash, hair color changes, high blood pressure, and fatigue. Some patients may also experience more severe side effects, such as bleeding problems, heart problems, and liver problems. These side effects can be serious and require immediate medical attention.
It's essential for patients to communicate any side effects or concerns to their healthcare provider. This allows the healthcare team to monitor the patient's condition closely and make necessary adjustments to the treatment plan.
Before starting Soranib 200 mg, patients should inform their healthcare provider about their medical history, including any existing health conditions, allergies, or medications they are currently taking. Soranib may interact with other medications, so a thorough discussion with the prescribing doctor is crucial.
Because Soranib can have adverse effects on the liver and kidneys, regular monitoring of liver and kidney function is necessary during treatment. Patients are also advised to use effective contraception methods during and for some time after treatment, as Soranib can harm unborn babies. It's essential for both men and women to discuss family planning with their healthcare provider while taking this medication.
Soranib 200 mg, with its active ingredient sorafenib, is a remarkable breakthrough in the treatment of certain types of cancer. By targeting specific molecular pathways, it offers new hope to patients facing advanced renal cell carcinoma, hepatocellular carcinoma, and certain forms of thyroid carcinoma. While the medication can cause side effects, its efficacy in slowing down cancer progression and extending the lives of patients is a testament to the progress made in cancer research and drug development. Soranib 200 mg should always be used under the supervision of a knowledgeable healthcare provider, who can tailor the treatment plan to the individual patient's needs and closely monitor their progress.
